Compounds and methods for inhibition of AP endonuclease-1/redox factor-1 (HAPE1) activity
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsBarry I. Gold, Xiangqun Xie, Ajay Srinivasan, LiRong Wang
Life of this patent
Estimating the term…
Abstract
A method for treating a neoplasm in a subject, comprising co-administering to the subject a therapeutically effective amount of an anticancer agent and a substituted 6,7-methylenedioxy-4-amino-quinoline, or a pharmaceutically acceptable salt or ester thereof.
Claims5
A method of inhibiting AP endonuclease-1/redox factor-1 (hAPE1) activity in a tumor cell resistant to DNA damaging agents comprising application to the tumor cell of a compound having the structure:
- wherein R1 is H, a C1-C5 alkyl group, which can be branched, unbranched, cyclic or acyclic, or a 3-5 member ring, which can be homocyclic or heterocyclic;
- R2 is H, or a C1-C5 branched, unbranched, cyclic or acyclic alkyl group, and R3 and R4 are independently and separately H, a C1-C5 alkyl group, which can be branched, unbranched, cyclic or acyclic, or a 3-5 member ring, which can be homocyclic or heterocyclic.
A method of inhibiting AP endonuclease-1/redox factor-1 (hAPE1) activity in a tumor cell resistant to DNA damaging agents comprising application to the tumor cell of a compound having the structure
A method of inhibiting AP endonuclease-1/redox factor-1 (hAPE1) activity in a tumor cell resistant to DNA damaging agents comprising application to the tumor cell of a compound having the structure:
A method for treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of
- or a pharmaceutically acceptable salt thereof,
- wherein the cancer is selected from human acute lymphoblastic leukemia, human chronic myelogenous leukemia, human myeloma, human large cell immunoblastic lymphoma, or human melanoma.
A method for treating glioma, wherein the glioma is resistant to a DNA damaging agent, in a subject, comprising co-administering to the subject a DNA damaging anticancer agent and a compound having a structure of:
- wherein R1 is H, a C1-C5 alkyl group, which can be branched, unbranched, cyclic or acyclic, or a 3-5 member ring, which can be homocyclic or heterocyclic;
- R2 is H, or a C1-C5 branched, unbranched, cyclic or acyclic alkyl group, and R3 and R4 are independently and separately H, a C1-C5 alkyl group, which can be branched, unbranched, cyclic or acyclic, or a 3-5 member ring, which can be homocyclic or heterocyclic.
Dependencies are inferred from the claim text.